Atlas Venture Fund XI, L.P.

October 16, 2026

Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.

October 10, 2026

Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.

September 29, 2026

Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer. Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.

October 3, 2026

ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.